Walleye Capital LLC Takes Position in NewAmsterdam Pharma (NASDAQ:NAMS)

Walleye Capital LLC bought a new position in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 46,947 shares of the company's stock, valued at approximately $779,000. Walleye Capital LLC owned about 0.05% of NewAmsterdam Pharma at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the business. Banque Cantonale Vaudoise acquired a new position in NewAmsterdam Pharma during the second quarter worth $38,000. Sei Investments Co. boosted its holdings in NewAmsterdam Pharma by 49.1% during the second quarter. Sei Investments Co. now owns 24,561 shares of the company's stock worth $472,000 after purchasing an additional 8,087 shares during the last quarter. Wolverine Asset Management LLC lifted its stake in NewAmsterdam Pharma by 117.7% in the second quarter. Wolverine Asset Management LLC now owns 15,524 shares of the company's stock valued at $298,000 after acquiring an additional 8,394 shares during the last quarter. TimesSquare Capital Management LLC lifted its stake in NewAmsterdam Pharma by 3.7% in the third quarter. TimesSquare Capital Management LLC now owns 255,245 shares of the company's stock valued at $4,237,000 after acquiring an additional 9,160 shares during the last quarter. Finally, GSA Capital Partners LLP lifted its stake in NewAmsterdam Pharma by 79.9% in the third quarter. GSA Capital Partners LLP now owns 66,402 shares of the company's stock valued at $1,102,000 after acquiring an additional 29,496 shares during the last quarter. Institutional investors and hedge funds own 89.89% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have commented on NAMS shares. Piper Sandler reiterated an "overweight" rating and issued a $37.00 price target on shares of NewAmsterdam Pharma in a research note on Monday, September 23rd. Royal Bank of Canada reiterated an "outperform" rating and issued a $31.00 price target on shares of NewAmsterdam Pharma in a research note on Thursday, September 5th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $36.00 price target on shares of NewAmsterdam Pharma in a research note on Thursday. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $33.80.

NewAmsterdam Pharma Price Performance

Shares of NAMS traded up $0.28 during trading hours on Friday, hitting $18.35. The company had a trading volume of 398,520 shares, compared to its average volume of 731,910. The business has a fifty day moving average of $19.87 and a 200-day moving average of $18.55. NewAmsterdam Pharma has a 12 month low of $8.90 and a 12 month high of $26.35.

Insider Activity

In related news, major shareholder Nap B.V. Forgrowth sold 8,530 shares of the firm's stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $25.02, for a total transaction of $213,420.60. Following the transaction, the insider now directly owns 11,812,033 shares of the company's stock, valued at approximately $295,537,065.66. This trade represents a 0.07 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Louise Frederika Kooij sold 45,000 shares of the firm's stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $15.72, for a total transaction of $707,400.00. The disclosure for this sale can be found here. Insiders have sold 86,803 shares of company stock valued at $1,755,307 over the last ninety days. 19.50% of the stock is currently owned by company insiders.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.